ABSTRACT: The Staphylococcus aureus chromosome harbors two homologues of the YefM-YoeB toxin−antitoxin (TA) system. The toxins YoeB Sa1 and YoeB Sa2 possess ribosomedependent ribonuclease (RNase) activity in Escherichia coli. This activity is similar to that of the E. coli toxin YoeB Ec , an enzyme that, in addition to ribosome-dependent RNase activity, possesses ribosome-independent RNase activity in vitro. To investigate whether YoeB Sa1 is also a ribosome-independent RNase, we expressed YoeB Sa1 using a novel strategy and characterized its in vitro RNase activity, sequence specificity, and kinetics. Y88 of YoeB Sa1 was critical for in vitro activity and cell culture toxicity. This residue was mutated to o-nitrobenzyl tyrosine (ONBY) via unnatural amino acid mutagenesis. YoeB Sa1 -Y88ONBY could be expressed in the absence of the antitoxin YefM Sa1 in E. coli. Photocaged YoeB Sa1 -Y88ONBY displayed UV light-dependent RNase activity toward free mRNA in vitro. The in vitro ribosome-independent RNase activity of YoeB Sa1 -Y88ONBY, YoeB Sa1 -Y88F, and YoeB Sa1 -Y88TAG was significantly reduced or abolished. In contrast to YoeB Ec , which cleaves RNA at both adenosine and guanosine with a preference for adenosine, YoeB Sa1 cleaved mRNA specifically at guanosine. Using this information, a fluorometric assay was developed and used to determine the kinetic parameters for ribosome-independent RNA cleavage by YoeB Sa1 . T oxin−antitoxin (TA) systems are genetic modules that are found in almost all free-living prokaryotes.
T oxin−antitoxin (TA) systems are genetic modules that are found in almost all free-living prokaryotes. 1 TA loci encode a protein toxin and a protein or RNA antitoxin and are grouped into five types on the basis of the mechanism by which the antitoxin counteracts the activity of the toxin. 2−4 In Type II TA systems, the antitoxin is a protein that binds to the toxin and prevents it from interacting with its cellular target. The activity of Type II toxins is regulated by the differential susceptibility of the toxin and the antitoxin to proteolysis. The antitoxin is more labile than the toxin and must be continuously expressed to maintain cellular levels capable of inhibiting the toxin. Toxin inhibition is relieved by the activity of cellular proteases, which degrade the labile antitoxin and shift the antitoxin:toxin ratio to favor the free toxin, which can then act on its cellular target. 5 The targets of TA system toxins include DNA replication, protein translation, and cell wall biosynthesis. Many toxins are ribonucleases (RNases) that inhibit translation by cleaving RNA in a ribosome-dependent or -independent fashion. 2 TA systems were originally discovered on plasmids, where they function as a postsegregational killing mechanism to maintain a plasmid in a bacterial population. If a daughter cell inherits a plasmid containing a TA locus during replication, both the antitoxin and the toxin will be expressed to form a stable, innocuous complex, and the cell will survive. However, if the plasmid is not inherited, rapid proteolytic degradation of the antitoxin will release the toxin to act on its cellular target and kill the cell, thereby eliminating plasmid-free cells from the population. 6 TA systems were subsequently discovered on the chromosomes of many bacteria and archaea. 1, 7 The function of chromosomally encoded TA systems is somewhat controversial, with at least 13 proposed roles, including junk DNA, selfish genes, stabilization of mobile genetic elements, anti-addiction elements, gene regulation, growth control/stress response, persistence, growth arrest, programmed cell death, phage defense, biofilm formation, virulence, and phenotypic bistability. 8, 9 However, it is generally accepted that cellular stress modulates transcription at the TA locus and stimulates degradation of the antitoxin, releasing the toxin to act on its cellular target and arrest growth until conditions become more favorable. 5 Upon the cessation of stress, the antitoxin is replenished, inactivating the toxin and allowing the cell to resume normal growth. 10 The growth arrest and eventual cell death resulting from toxin overexpression have led to the proposal that artificial toxin activation could provide an effective antibacterial strategy.
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The Gram-positive pathogen Staphylococcus aureus is the leading cause of bloodstream, lower respiratory tract, and skin and soft tissue infections worldwide. 15 A recent comparative genomic analysis identified between one and seven Type II TA loci in the sequenced genomes of 14 S. aureus strains, including YefM-YoeB Sa1 and YefM-YoeB Sa2 (previously identified as Axe1-Txe1 and Axe2-Txe2, respectively) 16, 17 that are homologues of the YefM-YoeB Ec TA system from Escherichia coli. 18 The toxin YoeB Ec possesses ribosome-independent RNase activity in vitro as well as ribosome-dependent RNase activity in vitro and in cells. 19, 20 YoeB Ec binds in the A site of the 50S ribosomal subunit, causing cleavage of mRNA transcripts three bases downstream of the start codon. 20 It is unknown whether YoeB Ec -mediated mRNA cleavage on the ribosome results from direct catalysis by YoeB Ec , from enhancement of the latent ribonucleolytic activity of the ribosome upon binding of YoeB Ec , or from some combination of the two. 20 A significant challenge when studying toxic proteins is the difficulty associated with their expression and purification in E. coli. Herein, we present a novel solution to this problem by incorporating a noncanonical amino acid, a photocaged tyrosine derivative, to replace a tyrosine that is critical for the activity and toxicity of YoeB Sa1 . Using protein produced through this method, the substrate specificity of YoeB Sa1 was unveiled, allowing the creation of a fluorogenic substrate that can be used to monitor YoeB Sa1 activity.
■ EXPERIMENTAL PROCEDURES
Bacterial Strains. MRSA clinical isolates were from a previously published collection. 21 E. coli DH5α and NiCo21-(DE3) were used for cloning and protein expression, respectively.
Primers. All primers used for polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), cloning, and sitedirected mutagenesis were synthesized by Integrated DNA Technologies (IDT) and are listed in Table S1 of the Supporting Information.
PCR Analysis of Clinical Isolates. Total DNA was previously purified from a diverse collection of 78 clinical isolates of MRSA. 21 Primers YefM-YoeB Sa1 -F and YefMYoeB Sa1 -R or YefM-YoeB Sa2 -F and YefM-YoeB Sa2 -R were used to amplify the yef M-yoeB Sa1 or yef M-yoeB Sa2 loci, respectively, from the total DNA. Primers YefM Sa1 -NdeI-F, YefM Sa1 -XhoI-R, YoeB Sa1 -NdeI-F, YoeB Sa1 -HindIII-R, YefM Sa2 -NdeI-F, YefM Sa2 -HindIII-R, YoeB Sa2 -NdeI-F, and YoeB Sa2 -HindIII-R were used to amplify the yef M Sa1 , yoeB Sa1 , yef M-yoeB Sa1 , yef M Sa2 , yoeB Sa2 , and yef M-yoeB Sa2 operons from the total DNA of strains NRS27 and NRS76. PCR amplification was performed on a DNA thermocycler using previously described reaction conditions. 21, 22 PCR products were separated by electrophoresis on 1% agarose gels and stained with ethidium bromide.
Sequencing Analysis. Approximately 10% of the PCR products generated via PCR amplification of the yef M-yoeB Sa1 and yef M-yoeB Sa2 loci were sequenced by the University of Illinois W. M. Keck Center for Comparative and Functional Genomics. Sequence data were analyzed using BioEdit version 7.0.5.3. The sequences were aligned using CLUSTAL W 23 and used as query sequences to search the BLAST database to verify the identity of the PCR products and homology to known genes. 24 RT-PCR Analysis of Clinical Isolates. MRSA isolates were streaked from glycerol stocks on Brain Heart Infusion (BHI) agar. Single colonies from freshly streaked plates were inoculated into 10 mL of BHI medium and incubated aerobically at 37°C with shaking at 250 rpm overnight (14− 16 h ). Overnight cultures were diluted 1:100 in 10 mL of BHI medium and incubated aerobically at 37°C with shaking at 250 rpm until the A 600 reached 0.6−1.0. Logarithmically growing cultures were harvested by centrifugation at 3220g for 10 min at 4°C. Total RNA was purified using the FastRNA Pro Blue Kit (Qbiogene) according to the manufacturer's instructions with the modification that lysis was performed by vortexing resuspended cells at maximal speed for 5 × 1 min pulses at room temperature with recovery for 1−5 min on ice between pulses. Isolated RNA was treated with DNase I and purified with reagents from the Total RNA Kit I (Omega Bio-Tek) according to the RNA Cleanup protocol from the RNeasy Mini Handbook (Qiagen). Purified total RNA (10 ng) was used in RT-PCR and in PCR with Platinum Taq DNA Polymerase (Invitrogen) to detect DNA contamination. RT-PCR was performed with primers YefM-YoeB Sa1 -F and YefM-YoeB Sa1 -R or YefM-YoeB Sa2 -F and YefM-YoeB Sa2 -R using the Superscript III One-Step RT-PCR System with Platinum Taq (Invitrogen) as previously reported 22 with the following modifications: the annealing temperature was increased to 55°C, and the number of cycles was reduced to 35. PCR products were separated by electrophoresis on 1% agarose gels and stained with ethidium bromide.
Construction of Plasmids.
The yoeB Sa1 open reading frame (ORF) was amplified via PCR from the total DNA of MRSA S4 21 with primers YoeB Sa1 -NdeI-F and YoeB Sa1 -Y88F-HindIII-R or YoeB Sa1 -Y88TAG-HindIII-R and cloned into the corresponding sites of pET-28a (Novagen) to create pET-28a-yoeB Sa1 -Y88F and pET-28a-yoeB Sa1 -Y88TAG, respectively. The yef M-yoeB Sa1 ORF was amplified via PCR from the total DNA of MRSA S4 21 with primers YefM Sa1 -NdeI-F and YoeB Sa1 -HindIII-R and cloned into the corresponding sites of pET-28a. Because a single nonsilent point mutation was found in the sequence for YefM Sa1 , Quikchange site-directed mutagenesis was performed with primers YefM Sa1 -QC-F and YefM Sa1 -QC-R to create pET-28a-yef M-yoeB Sa1 . Site-directed mutagenesis was carried out with the Quikchange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions with the modification that E. coli DH5α was used as the host strain. The yef M Sa1 ORF was amplified via PCR from the total DNA of MRSA NRS3 (Network on Antimicrobial Resistance in S. aureus) with primers YefM Sa1 -NdeI-F and YefM Sa1 -XhoI-R and cloned into the corresponding sites of pET-28a to create pET28a-yef M Sa1 . All clones were confirmed by sequencing. The following antibiotic concentrations were used: 50 μg/mL kanamycin (pET-28a), 35 μg/mL chloramphenicol (pEVOL-ONBY), and 100 μg/mL ampicillin (Pentaprobes).
ONBY Synthesis. o-Nitrobenzyl tyrosine (ONBY) was synthesized according to a previously published method 25 with some modifications. Two grams (11 mmol) of L-tyrosine was stirred with 1.9 g (7.6 mmol) of CuSO 4 ·5H 2 O in 20 mL of 1 M NaOH at 60°C for 20 min. The reaction was cooled to room temperature, quenched with hydrochloric acid, filtered, and washed with water. The resulting solid was stirred with 1.5 g (11 mmol) of K 2 CO 3 and 1.8 g (8.3 mmol) of o-nitrobenzyl bromide in 60 mL of 75% aqueous dimethylformamide (DMF) at room temperature in the dark for 3 days. The resulting solid was filtered; washed with 75% aqueous DMF, water, 75% aqueous acetone, and ice-cold acetone; stirred in 100 mL of 1 M HCl for 2 h; filtered; stirred in 100 mL of 1 M HCl for 1 h; filtered; and washed with water and acetone. The overall yield was 1.8 g (5.7 mmol, 69%).
Purification of YoeB Sa1 -Y88F and YoeB Sa1 -Y88TAG. pET-28a-yoeB Sa1 -Y88F or pET-28a-yoeB Sa1 -Y88TAG was introduced into E. coli NiCo21(DE3). A single colony from a freshly streaked plate was inoculated into LB medium supplemented with kanamycin and grown at 37°C with shaking at 250 rpm overnight (14−16 h). The overnight culture was diluted 1:100 and grown at 37°C with shaking at 250 rpm until the A 600 reached 0.4−0.6. Protein expression was induced with 1 mM IPTG at 37°C with shaking at 250 rpm for 4 h. The culture was harvested by centrifugation at 6000g for 5 min at 4°C. Cell pellets were frozen at −20°C, thawed on ice for 30 min, and resuspended in 10 mL of cold lysis buffer [20 mM Tris, 500 mM NaCl, and 60 mM imidazole (pH 7.9)]. Cells were lysed by sonication on ice at 40% amplitude for 5 min with a 1 s pulse. The lysate was cleared by centrifugation at 35000g for 30 min at 4°C. The supernatant was batch-loaded onto 1 mL of 1:1 Ni-NTA agarose (Qiagen) at 4°C for 30 min with inversion. The resin was washed with 20 mL of cold lysis buffer and eluted with 10 mL of cold elution buffer A [50 mM Tris, 500 mM NaCl, 500 mM imidazole, 1 mM TCEP, and 10% glycerol (pH 7.9)]. The eluted fraction was concentrated to ∼0.5 mL using an Ultra-15 Centrifugal Filter Unit with an Ultracel-3 membrane (Amicon), 0.2 μm filtered, and further purified on a HiLoad 16/60 Superdex 75 PG column (GE Healthcare) using fast performance liquid chromatography (FPLC) buffer A [50 mM Tris, 200 mM NaCl, 1 mM TCEP, and 10% glycerol (pH 7.9)]. Fractions containing pure protein were pooled and concentrated to ∼0.5−1 mL. Purity was assessed by sodium dodecyl sulfate−polyacrylamide gel electrophoresis (SDS−PAGE) using 4−20% TGX Mini-PROTEAN gels (Bio-Rad). The concentration was determined by densitometry and by the bicinchoninic acid (BCA) assay (Pierce) performed according to the manufacturer's instructions, with the modification that lysozyme standards were used instead of bovine serum albumin (BSA) standards.
Purification of YoeB Sa1 -Y88ONBY. pET-28a-yoeB Sa1 -Y88TAG and pEVOL-ONBY were introduced into E. coli NiCo21(DE3). A single colony from a freshly streaked plate was inoculated into LB medium supplemented with kanamycin and chloramphenicol and grown at 37°C with shaking at 250 rpm overnight (14−16 h). The overnight culture was diluted 1:100, 100 mM ONBY dissolved in 1 M NaOH was added to a final concentration of 1 mM, and the culture was grown at 37°C with shaking at 250 rpm in the dark. When the A 600 of the culture reached 0.5−0.6, arabinose was added to a final concentration of 0.2% to induce expression of ONBY-aaRS. When the A 600 of the culture reached 1.0−1.2, IPTG was added to a final concentration of 1 mM to induce expression of YoeB Sa1 -Y88ONBY. Expression was allowed to proceed at 37°C for 15 h. The culture was harvested, and YoeB Sa1 -Y88ONBY was purified in the dark as described above for YoeB Sa1 -Y88F and YoeB Sa1 -Y88TAG.
Purification of YefM Sa1 . pET-28a-yef M Sa1 was introduced into E. coli NiCo21(DE3), and protein expression and purification were performed as described for YoeB Sa1 -Y88F and YoeB Sa1 -Y88TAG, with the modification that YefM Sa1 was eluted with 10 mL of cold elution buffer B [20 mM Tris, 500 mM NaCl, and 500 mM imidazole (pH 7.9)]. Gel filtration was performed twice using FPLC buffer B [20 mM Tris and 500 mM NaCl (pH 7.9)] to remove RNase contamination. Fractions corresponding to the second major peak from the first gel filtration step were pooled, concentrated, and subjected to a second gel filtration step. Fractions corresponding to the second major peak from the second gel filtration step were pooled, concentrated, and used in experiments. Purity was assessed by SDS−PAGE using 4−20% TGX Mini-PROTEAN gels (Bio-Rad). Protein concentration was determined by the BCA assay (Pierce) performed according to the manufacturer's instructions using BSA standards.
ESI-MS.
Five micrograms of YefM Sa1 , YoeB Sa1 -Y88F, YoeB Sa1 -Y88TAG, or YoeB Sa1 -Y88ONBY was precipitated according to a previously published method. 26 YoeB Sa1 -Y88ONBY was exposed to 312 nm light on a UV transilluminator for 0−600 s prior to precipitation. Precipitated, airdried protein was analyzed by electrospray ionization mass spectrometry (ESI-MS) at the University of Illinois Mass Spectrometry Laboratory.
Agarose Gel RNase Activity Assay. pET-28a-yef MyoeB Sa1 was digested with XhoI (NEB) at 37°C for 3 h. The fully linearized plasmid was extracted once with a 24.5:24.5:1 phenol/chloroform/isoamyl alcohol mixture and twice with chloroform, precipitated with 3 M NaOAc (pH 5.3) and 100% EtOH, and resuspended in nuclease-free water. One microgram of linearized plasmid was used as the template for standard RNA synthesis with the T7 High Yield RNA Synthesis Kit (NEB) according to the manufacturer's instructions. RNA was purified with reagents from Total RNA Kit I (Omega Bio-Tek) according to the RNA Cleanup protocol from the RNeasy Mini Handbook (Qiagen). RNase assays were performed according to a modified published method. 19 For the light dependence of decaging, 10 pmol of YoeB Sa1 -Y88ONBY in 50 mM Tris and 5% glycerol (pH 8.0) was exposed to UV light for 0−5 min, followed by the addition of 320 ng of yef M-yoeB Sa1 RNA with Human Placental RNase Inhibitor (NEB) at a final concentration of 1 unit/μL. Reactions were incubated at 37°C for 2 h and quenched by addition of 1 μg of proteinase K (Invitrogen) and incubation at 37°C for 15 min. Eleven microliters of RNA loading dye I (95% formamide, 18 mM EDTA, 0.025% SDS, and 0.025% bromophenol blue) was then added, and samples were incubated at 95°C for 5 min immediately prior to electrophoresis on 1.2% agarose, 0.5× TBE [45 mM Tris-borate and 1 mM EDTA (pH 8.3)], 0.1 μg/ mL ethidium bromide gels. For the inhibition of YoeB Sa1 by YefM Sa1 , YoeB Sa1 (10, 20, or 30 pmol) in 50 mM Tris and 5% glycerol (pH 8.0) was exposed to UV light for 3 min. YefM Sa1 (0, 10, 20, or 30 pmol) was then added. Following incubation at 37°C for 30 min to allow formation of the YefMYoeB Sa1 complex, 320 ng of yef M-yoeB Sa1 RNA was added with Human Placental RNase Inhibitor at a final concentration of 1 unit/μL. Reactions were incubated at 37°C for 1 h, quenched, and analyzed as described above. For the time course of YoeB Sa1 and YefM Sa1 RNase activity, 10 pmol of YoeB Sa1 -Y88ONBY, YoeB Sa1 -Y88F, YoeB Sa1 -Y88TAG, or YefM Sa1 was incubated with 320 ng of yef M-yoeB Sa1 RNA in the presence of 1 unit/μL Human Placental RNase Inhibitor in 50 mM Tris and 5% glycerol (pH 8.0). One set of reactions containing YoeB Sa1 -Y88ONBY was exposed to UV light for 3 min prior to the addition of RNA. Reactions were incubated at 37°C for 1− 20 h, quenched, and analyzed as described above.
Polyacrylamide Gel RNase Activity Assay. Quikchange site-directed mutagenesis was performed with primers PP1QC1-F and PP1QC1-R to insert a G into Pentaprobe 1 and with primers PP1QC2-F and PP1QC2-R, PP2QC-F and PP2QC-R, PP4QC-F and PP4QC-R, PP6QC-F and PP6QC-R, PP7QC-F and PP7QC-R, PP8QC-F and PP8QC-R, PP9QC-F and PP9QC-R, PP10QC-F and PP10QC-R, and PP12QC-F and PP12QC-R (Table S1 of the Supporting Information) to introduce XbaI sites into Pentaprobes 1, 2, 4, 6−10, and 12, respectively. Site-directed mutagenesis was carried out with the Quikchange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions, with the modification that E. coli DH5α was used as the host strain. Pentaprobe plasmids were digested with XbaI (NEB) at 37°C for 3 h. Fully linearized plasmids were purified by phenol/chloroform extraction as described above. RNA was synthesized and purified as described above. RNase assays were performed according to a modified published method. 27 One microgram of YoeB Sa1 -Y88ONBY was incubated with 1 μg of Pentaprobe RNA in 50 mM Tris (pH 8.0) for 0.5−2 h at 37°C. Reactions were quenched by addition of 1 μg of proteinase K and incubation at 37°C for 15 min. An equal volume of RNA loading dye II (95% formamide, 5 mM EDTA, and 0.025% bromophenol blue) was then added, and the reactions were incubated at 95°C for 5 min to denature the RNA. The products were visualized by electrophoresis on 8% polyacrylamide TBE−urea gels [89 mM Tris-borate, 2 mM EDTA, and 8 M urea (pH 8.
3)] poststained with ethidium bromide.
Matrix-Assisted Laser Desorption Ionization (MALDI) RNase Activity Assay. PP7-1, PP7-2, and PP7-3 were synthesized by Genscript. Ten micrograms of YoeB Sa1 -Y88ONBY was incubated with 2 μg of oligonucleotide for 1 or 2 h at 37°C. Reactions were quenched by addition of 10 μg of proteinase K (Invitrogen) and incubation at 37°C for 30 min followed by precipitation with 5 M NH 4 OAc (final concentration of 2 M) and 3 volumes of 100% EtOH at −80°C
. Pellets were washed with ice-cold 70% EtOH, resuspended in 1 μL of H 2 O, and analyzed by matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) at the University of Illinois Mass Spectrometry Laboratory.
High-Performance Liquid Chromatography (HPLC) RNase Activity Assay. The fluorogenic chimeric oligonucleotide substrate 5′-6-FAM-AACrArArArArGrArArAAATTIABkFQ-3′ (6-FAM, 6-carboxyfluorescein fluorophore; IABkFQ, Iowa Black fluorophore quencher) and cleavage products 5′-6-FAM-AACrArArArArG-3′ and 5′-rArArAAATTIABkFQ-3′ were synthesized by IDT. YoeB Sa1 (20 μM) was incubated with oligonucleotide (30 μM) in buffer at 25°C for 5 h. HPLC was performed using an Alliance HPLC System (e2695 Separations Module, Waters) with detection at 260 nm (2489 UV/visible Detector, Waters). The full-length oligonucleotide was separated from the cleavage products on a YMCbasic S5 column (4.6 mm × 150 mm, 5 μm, Waters) using a linear gradient from 100 mM triethylammonium acetate (TEAA) (pH 7.0) to a mixture of 50 mM TEAA and 50% acetonitrile (pH 7.0) over 25 min. Peak fractions were collected, concentrated to 5−10 μL, and analyzed by MALDI-MS at the University of Illinois Mass Spectrometry Laboratory.
Fluorometric Assay. Wells of a black 384-well plate were filled with 15 μL of 0.5−20 μM intact fluorogenic substrate or cleavage products diluted in assay buffer [200 mM sodium phosphate (pH 6.0) and 5% glycerol] and allowed to equilibrate for 30 min at room temperature. YoeB Sa1 -Y88ONBY was diluted to 10 μM in assay buffer, exposed to UV light at 312 nm for 3 min, and added to wells containing intact substrate or cleavage products to a final concentration of 5 μM. Fluorescence was measured once every minute for 100 min using a Criterion Analyst AD instrument (Molecular Devices) with 485 ± 15 nm excitation and 530 ± 15 nm emission filters and a 505 nm cutoff dichroic mirror. The fluorophore was excited with a 1000 W continuous xenon arc lamp with 10 reads per well. Three separately purified batches of YoeB Sa1 -Y88ONBY were each assayed in technical triplicate on two different days. Results are the average of the average rate for each batch of protein.
Calibration Plot. Fluorescence values for 1:1 molar mixtures of the cleavage products at 30 min after addition of YoeB Sa1 were used to construct a calibration plot of picomoles of cleaved substrate versus relative fluorescence units (RFU). A separate calibration plot was constructed each time the fluorometric assay was performed.
Kinetic Analysis. In some of the progress curves, an increase in fluorescence was not observed until ∼15 min after the addition of YoeB Sa1 . However, the increase in measured fluorescence was linear over the majority of the remainder of the assay. Consequently, initial rates were calculated from the linear portion of the progress curves between 20 and 30 min. Fluorescence values were corrected by subtracting the fluorescence measured at 20 min from all subsequent time points. Corrected fluorescence values were converted to picomoles of cleaved substrate using the slope from the calibration plot, and linear regression was performed using Microsoft Excel to obtain initial velocities. Linear velocities were plotted versus substrate concentration, and the resulting data points were fit with the Hill equation using OriginPro version 8.0.
■ RESULTS
Prevalence, Conservation, and Transcription of yef MyoeB Sa1 and yef M-yoeB Sa2 in MRSA Clinical Isolates. The artificial activation of TA systems is of significant interest as an intriguing antibacterial strategy.
11−14 YoeB Sa1 and YoeB Sa2 specifically present outstanding targets for this approach, as expression of YoeB Sa1 and YoeB Sa2 in the absence of their respective antitoxins, YefM Sa1 and YefM Sa2 , induces growth arrest in E. coli. 28 For artificial activation of YoeB Sa1 or YoeB Sa2 to be an effective antibacterial strategy, YefM-YoeB Sa1 and YefM-YoeB Sa2 must be present and functional in clinical isolates of S. aureus. Thus, the presence, conservation, and transcription of yef M-yoeB Sa1 and yef M-yoeB Sa2 were investigated in a collection of 78 clinical isolates of MRSA from three Illinois hospitals and the Network on Antimicrobial Resistance in S. aureus (NARSA). Multiple-locus variable number of tandem repeats analysis previously confirmed that these isolates were not clonal. 21 The total DNA of these isolates was probed for the presence of yef M-yoeB Sa1 and yef M-yoeB Sa2 using PCR with intragenic specific primers ( Figure 1A ). The yef M-yoeB Sa1 and yef MyoeB Sa2 genes were present in 99% (77 of 78) of the clinical isolates (Table S2 of the Supporting Information). Approximately 10% of the PCR products were subjected to DNA sequencing, and the sequences were aligned with the reference genome from the S. aureus COL strain using CLUSTAL W 23 (Figures S1 and S2 of the Supporting Information) and compared with yef M-yoeB Sa1 and yef M-yoeB Sa2 loci from published S. aureus genomes using BLAST. 24 The yef M-yoeB Sa1 PCR products were >97% identical with the yef M-yoeB Sa1 genes in 29 of the 30 genomes containing that locus, while the yef MyoeB Sa2 PCR products were at least 96% identical with the yef M-yoeB Sa2 genes in all 26 genomes containing that locus.
PCR products of ∼1.3 and ∼2.5 kb resulted from attempts to detect yef M-yoeB Sa1 and yef M-yoeB Sa2 , respectively, in NRS27. DNA sequence analysis revealed that the product amplified by yef M-yoeB Sa1 -specific primers spanned a phage transcriptional repressor and a DNA polymerase III α subunit, while the product amplified by yef M-yoeB Sa2 -specific primers spanned an ornithine cyclodeaminase, a siderophore biosynthesis protein, and a multidrug resistance efflux pump. Sites of partial complementarity were identified between the yef M-yoeB Sa1 -and yef M-yoeB Sa2 -specific primers and these genes, which could allow amplification in the absence of yef M-yoeB Sa1 and yef MyoeB Sa2 . To confirm the absence of yef M-yoeB Sa1 and yef MyoeB Sa2 in NRS27, the yef M Sa1 , yoeB Sa1 , yef M-yoeB Sa1 , yef M Sa2 , yoeB Sa2 , and yef M-yoeB Sa2 operons were individually amplified using primers designed to clone each of the full genes. PCR products were detected in the positive control strain NRS76, but not in NRS27. These results indicate that the yef M-yoeB Sa1 and yef M-yoeB Sa2 genes are not present in NRS27.
To investigate the transcription of yef M-yoeB Sa1 and yef MyoeB Sa2 in MRSA, RT-PCR was performed on total RNA from eight isolates using the same primers used in the PCR screen. yef M-yoeB Sa1 and yef M-yoeB Sa2 were transcribed as bicistronic messages in each of the strains ( Figure 1B) . No PCR products were detected in the absence of reverse transcriptase, indicating the absence of DNA contamination. Taken together, these results suggest that yef M-yoeB Sa1 and yef M-yoeB Sa2 are widespread, conserved, and transcribed in clinical MRSA isolates. Thus, an activator of YoeB Sa1 or YoeB Sa2 with antibacterial activity could have broad efficacy against S. aureus.
Photocaging Allows Expression of YoeB Sa1 in E. coli. YoeB Ec exhibits ribosome-dependent RNase activity in vitro and in E. coli. 20 YoeB Sa1 and YoeB Sa2 were found to exhibit RNase activity similar to that of YoeB Ec upon overexpression in E. coli, suggesting that they are ribosome-dependent RNases with the same mechanism of action as YoeB Ec . 28 Intriguingly, YoeB Ec also possesses "residual" ribosome-independent RNase activity. 19 Evaluation of the possibility that YoeB Sa1 and YoeB Sa2 might also possess such activity necessitates the expression and purification of full-length, functional YoeB Sa1 and YoeB Sa2 . However, YoeB Sa1 and YoeB Sa2 inhibit translation initiation and induce growth arrest in E. coli, 28 effectively preventing overexpression and characterization. As yef M-yoeB Sa1 proved to be more amenable to manipulation using standard molecular biology techniques than yef M-yoeB Sa2 , a number of strategies were explored in efforts to obtain pure, functional YoeB Sa1 .
The most common method employed to obtain a functional TA system toxin for in vitro characterization involves coexpression of the antitoxin with the toxin, purification of the resulting TA complex, isolation of the toxin by denaturation of the complex, and subsequent refolding. Active YoeB Ec has been obtained by dissociation from YefM Ec in 6 M guanidine hydrochloride (GuHCl) followed by refolding via gradual dialysis into HEPES buffer. 19 YoeB Ec and YoeB Sa1 share a high degree of sequence homology, suggesting that a similar method could allow purification of functional YoeB Sa1 . The yef MyoeB Sa1 operon was therefore cloned into pET-28a with a hexahistidine tag at the N-terminus of YefM Sa1 to facilitate purification, and the complex was expressed in E. coli and purified using Ni-NTA resin. A variety of conditions were screened to identify an optimal method for denaturing, purifying, and refolding YoeB Sa1 . In each case, the YefMYoeB Sa1 complex was denatured by extended dialysis against either 6 M GuHCl or 8 M urea, YefM Sa1 was extracted with Ni-NTA resin, and the presence and purity of the remaining YoeB Sa1 were assessed using SDS−PAGE. If 6 M GuHCl was used as the denaturant, the recaptured YefM Sa1 was highly pure, but YoeB Sa1 was not recovered in the unbound fraction, probably because of the low initial ratio of YoeB Sa1 to YefM Sa1 and the necessity of diluting and precipitating samples containing GuHCl for SDS−PAGE. In contrast, when 8 M urea was used as the denaturant, YoeB Sa1 was recovered, but a significant amount of residual YefM Sa1 was also present. Efforts to refold the impure toxin by dilution or gradual dialysis resulted in substantial precipitation. These unpromising results led to the abandonment of denaturing purification and refolding as a viable approach to obtaining large quantities of pure, active YoeB Sa1 .
An alternative to denaturing purification of the toxin from the TA complex is to use a commercially available protease to selectively degrade the labile antitoxin from the TA complex, leaving the toxin unscathed. 27 The YefM-YoeB Sa1 complex was expressed and purified as described above and subjected to digestion with trypsin. Analysis of the digest products by SDS− PAGE suggested that YoeB Sa1 remained intact while YefM Sa1 was rapidly and selectively degraded. However, the YoeB Sa1 protein obtained from trypsin digestion of YefM-YoeB Sa1 did not bind to YefM Sa1 in pull-down experiments. Native PAGE of the digestion time course suggested that a fragment of YefM Sa1 remained bound to YoeB Sa1 , prohibiting complex formation and indicating that this approach could not be used to obtain pure YoeB Sa1 . The yoeB Sa1 gene was then cloned at the C-terminus of glutathione S-transferase (GST) in hopes that a larger fusion partner would reduce the toxicity of YoeB Sa1 by preventing it from binding to the ribosome. However, all sequenced clones contained frameshift mutations introducing premature stop codons in the yoeB Sa1 gene. Two rounds of site-directed mutagenesis were performed to correct these mutations. Additional premature stop codons or inactivating mutations were introduced in each round, suggesting that low levels of full-length GST-YoeB Sa1 , produced by leaky expression from the T7 promoter even in the absence of T7 RNA polymerase, retained the ability to bind to the ribosome, inhibit translation, induce growth arrest, and prevent colony formation. Only mutant clones encoding premature stop codons were not toxic. These results hinted that the C-terminal region of YoeB Sa1 is necessary for activity and toxicity. As the C-terminal residues H83 and Y84 of YoeB Ec are required for both in vitro RNase activity and toxicity in E. coli, 19 the inability to clone the fulllength yoeB Sa1 gene at the C-terminus of GST suggested that the analogous H87 and Y88 in YoeB Sa1 have similar roles.
Mutation of the C-terminal Y84 of YoeB Ec to phenylalanine or alanine was previously found to diminish both in vitro RNase activity and toxicity in E. coli, 19 suggesting that similar mutations to the homologous C-terminal Y88 of YoeB Sa1 might sufficiently reduce toxicity to allow expression in E. coli. To investigate the contribution of Y88 to the toxicity of YoeB Sa1 , the TAT codon for Y88 in YoeB Sa1 was changed to TAG for the amber stop codon (Y88TAG) or to TTT for phenylalanine (Y88F). The genes encoding these mutants were cloned into pET-28a and expressed in E. coli. The resulting proteins were purified with yields of 5 mg of YoeB Sa1 -Y88TAG and 2.5 mg of YoeB Sa1 -Y88F per liter of culture. ESI mass spectrometry (ESI-MS) showed that the molecular masses of these mutants matched the predicted values [YoeB Sa1 -Y88TAG, expected molecular mass of 12307 Da and observed molecular mass of 12303 Da ( Figure 2A) ; YoeB Sa1 -Y88F, expected molecular mass of 12454 Da and observed molecular mass of 12450 Da (Figure 2B) ]. These results indicated that Y88 contributes to YoeB Sa1 toxicity in E. coli and suggested that a nonpermanent modification of the structure of Y88 might sufficiently alleviate the toxicity of YoeB Sa1 to allow expression of the full-length protein in E. coli.
Unnatural amino acid (UAA) mutagenesis allows the incorporation of a noncanonical amino acid site-specifically into a protein via the use of an aminoacyl-tRNA synthetase (aaRS)/tRNA pair that is orthogonal to the host organism's translational machinery. 29−31 The photocaged UAA o-nitrobenzyl tyrosine (ONBY) has been incorporated into a number of proteins in which a tyrosine is critical for enzymatic activity.
32−36 Mutation of tyrosine to ONBY "cages" the enzyme by inhibiting catalysis, substrate binding, or both. Irradiation with UV light between 300 and 365 nm releases the photocaging o-nitrobenzyl group, 37 revealing the free tyrosine and activating the enzyme for catalysis. As Y88 contributes to the toxicity and, presumably, the activity of YoeB Sa1 , it was hypothesized that mutation of Y88 to ONBY would allow expression of an inactive, nontoxic YoeB Sa1 variant that could be activated by UV light following expression and purification.
The pEVOL plasmids for UAA mutagenesis encode an optimized amber (TAG) stop codon suppressor tRNA and two copies of an evolved UAA-specific Methanocaldococcus jannaschii aaRS, one under the control of a constitutive glnS′ promoter and the other under the control of an arabinoseinducible araBAD promoter, which allows the expression level of the aaRS to be finely tuned. 38 As Y88 is the last residue in YoeB Sa1 , it would be challenging to purify ONBY-containing YoeB Sa1 from prematurely truncated YoeB Sa1 . A variety of expression conditions were therefore screened by ESI-MS for maximal incorporation of ONBY into YoeB Sa1 . Maximal incorporation was achieved when 1 mM ONBY was present in the culture medium from the beginning of the expression, when aaRS expression was induced in early logarithmic growth phase, and when YoeB Sa1 expression was induced in late logarithmic or early stationary phase and allowed to proceed overnight at 37°C. Using this method, 1 mg of pure YoeB Sa1 -Y88ONBY was obtained per liter of culture. ESI-MS revealed that the mass of the full-length caged protein was ∼30 Da lower than predicted [YoeB Sa1 -Y88ONBY, expected molecular mass of 12606 Da and observed molecular mass of 12574 Da ( Figure  2C) ]. This discrepancy is attributed to reduction of the nitro group of ONBY to an amino group, a phenomenon that has been observed when ESI-MS is performed in protic solvents, resulting in a loss of 30 Da that corresponds to the observed mass shift. 39 Importantly, very little truncated YoeB Sa1 -Y88TAG was present (expected molecular mass of 12307 Da and observed molecular mass of 12305 Da). UV light-induced loss of the o-nitrobenzyl moiety was followed by ESI-MS [YoeB Sa1 -Y88, expected molecular mass of 12470 ( Figure 2D−H) ]. The extent of decaging increased as the extent of UV exposure was increased up to 3 min, after which no further decaging was observed ( Figure 2F−H) .
Decaged YoeB Sa1 Is a Ribosome-Independent RNase. The ribosome-independent RNase activity of YoeB Sa1 was assessed with respect to yef M-yoeB Sa1 RNA in vitro. Decaging of YoeB Sa1 -Y88ONBY resulted in UV light-dependent degradation of the RNA ( Figure 3A ). In agreement with ESI-MS data showing that the extent of decaging did not increase with additional UV exposure after 3 min (Figure 2F ), the RNase activity of YoeB Sa1 -Y88ONBY also did not increase with additional UV exposure after 3 min ( Figure 3A) . YoeB Sa1 activity was inhibited by the addition of an equimolar amount of YefM Sa1 (Figure 3B ), demonstrating that the observed RNase activity was due specifically to YoeB Sa1 and not to RNase contamination. This result also suggests that YefM Sa1 inhibits YoeB Sa1 at a 1:1 ratio, which is identical to the ratio of YefM Ec to YoeB Ec required to inhibit YoeB Ec in a similar in vitro assay. 19 Comparison of the activity of decaged YoeB Sa1 with that of YoeB Sa1 mutants and YefM Sa1 reveals that YoeB Sa1 -Y88ONBY retains weak in vitro RNase activity, YoeB Sa1 -Y88F degrades RNA very slowly, and no detectable RNase activity is observed for YoeB Sa1 -Y88TAG or YefM Sa1 ( Figure 3C ).
YoeB Sa1 Cleaves RNA after Guanosine Residues. The Pentaprobes are a set of 12 plasmids that together encode every possible combination of five nucleotides in sequences of ∼100 nucleotides per plasmid. 40 The Pentaprobes have been used to determine the sequence specificity of RNases with recognition sequences of five or fewer nucleotides. Cleavage of each Pentaprobe by the RNase of interest is assessed by PAGE. Once cleaved Pentaprobes are identified, deconvolution occurs via MALDI-MS analysis of cleavage of small oligonucleotides. 27 The RNase activity of YoeB Sa1 toward each of the 12 Pentaprobe RNA transcripts was assessed by denaturing PAGE. YoeB Sa1 was least active toward Pentaprobe 1 and most active toward Pentaprobes 4, 7, and 10 ( Figure 4A ; other Pentaprobes not shown). Cleavage of Pentaprobe 7 was the most dramatic, with rapid and significant degradation of the full-length parent band and the appearance of a number of smaller discrete product bands, indicating that YoeB Sa1 cleaves this Pentaprobe at multiple sites. The sequence of Pentaprobe 7 is rich in purine residues ( Figure 4B ), suggesting that the sequence specificity of YoeB Sa1 might be similar to that of YoeB Ec , which cleaves RNA after purine residues with a preference for adenosine. 19 To identify the specific sequence recognized and cleaved by YoeB Sa1 within Pentaprobe 7, cleavage of three overlapping oligonucleotides spanning Pentaprobe 7 ( Figure 4B ) was assessed by MALDI-MS. YoeB Sa1 cleaved each oligonucleotide selectively after guanosine, leaving a 3′-cyclic phosphate on the 5′-RNA product. This suggests that YoeB Sa1 is a guanosinespecific RNase in vitro and furthermore that the mechanism of YoeB Sa1 RNA cleavage involves activation of the 2′-OH for nucleophilic attack of the 3′-phosphodiester bond. Fragments corresponding to both the 5′-and 3′-products were observed for 5 of the 9 guanosines in PP7-1, 6 of 13 in PP7-2, and 1 of 4 in PP7-3. Most of the noncleaved guanosines were near the termini of the oligonucleotides, which reduces the likelihood of observing cleavage at these sites by MALDI because of the 2 kDa lower mass limit of the detector and a reduction in MALDI sensitivity with an increase in oligonucleotide length. YoeB Sa1 may also require a minimum number of residues 5′ or 3′ from the cleavage site to bind and cleave RNA and thus may skip guanosines near the termini of an oligonucleotide.
In the consensus sequence cleaved by YoeB Sa1 , adenosine residues precede and follow the guanosine at the cleavage site ( Figure 4C ). This may be an artifact of oligonucleotide design and selection, as most of the guanosines in Pentaprobe 7 are preceded by one or more adenosines. However, it is also possible that YoeB Sa1 prefers to cleave after guanosines in the midst of purine-rich sequences. The fact that YoeB Sa1 cleaved PP7-3 at only one of the three internal guanosines suggests that the ability of YoeB Sa1 to cleave free mRNA may be inhibited by secondary structure, as PP7-3 had more predicted secondary structure than PP7-1 and PP7-2, which may have limited the ability of YoeB Sa1 to access other potential cleavage sites in PP7-3.
Kinetic Characterization of YoeB Sa1 RNase Activity. With the objective of developing a YoeB Sa1 substrate that could be used to assess the activation of this RNase in a highthroughput setting, a fluorogenic oligonucleotide substrate was designed based on the data presented in Figure 4 . An analogous design was previously used for the creation of a substrate for the ribosome-independent RNase MazF. 41, 42 One of the sequences from PP7 that was cleaved by YoeB Sa1 was converted into a 15-mer chimeric oligonucleotide with eight internal RNA residues surrounded by DNA nucleotides for stability ( Figure  5A ). Cleavage of this substrate was predicted to occur after the central guanosine residue. A 6-carboxyfluorescein fluorophore (excitation at 495 nm and emission at 520 nm) and an Iowa Black FQ quencher (absorbance maximum at 530 nm) were appended to the 5′-and 3′-ends, respectively, of the oligonucleotide. In the intact substrate, proximity allows the quencher to absorb the fluorescence emitted by the fluorophore. Cleavage of the substrate increases the distance between the fluorophore and the quencher, producing an increase in fluorescence that can be monitored spectrophotometrically.
The ability of YoeB Sa1 to cleave this substrate was assessed by HPLC. The retention times of the products from YoeB Sa1 activity overlapped with those of the independently synthesized standards ( Figure 5B ), suggesting that cleavage occurred primarily at guanosine, as predicted. MALDI-MS analysis of fractions collected from the elution peaks confirmed that the majority of cleavage events occurred at guanosine ( Figure S3 of the Supporting Information). These results corroborate the guanosine specificity of YoeB Sa1 ribosome-independent RNase activity. 19 To determine the kinetic parameters of YoeB Sa1 as a baseline for future high-throughput screening efforts, the RNase activity of YoeB Sa1 toward the fluorogenic substrate was assessed in 384-well plate format. YoeB Sa1 (5 μM) was incubated with a range of concentrations of the fluorogenic substrate (0.5−20 μM) to produce a set of progress curves (representative data from one replicate of one experiment shown in Figure 5C ). For each experiment, a calibration curve was constructed by mixing the two chimeric products resulting from YoeB Sa1 cleavage at a 1:1 molar ratio in the presence of YoeB Sa1 (5 μM). The relationship between the measured fluorescence and the concentration of the cleavage products was linear up to 1.5 μM. This calibration curve was used to convert relative fluorescence units (RFU) at 530 nm to picomoles of cleaved substrate. Ideally, initial rates would be measured immediately following addition of YoeB Sa1 to the substrate. However, in some experiments, a significant increase in fluorescence was not observed until ∼15 min after the addition of YoeB Sa1 . Consequently, the rates plotted in Figure 5D were determined from the linear portion of the progress curves between 20 and 30 min. Traditional Michaelis−Menten enzyme kinetics are characterized by a hyperbolic rate, V, versus substrate concentration, [S] , curve that can be fit by the equation
where V max is the maximal reaction velocity and K m is the Michaelis constant, equal to the substrate concentration at which half-maximal activity is observed. This equation describes a hyperbolic rate that increases linearly when [S] is low and asymptotically approaches V max at high values of [S]. 43, 44 The rate data in Figure 5D reveal that the kinetics of YoeB Sa1 RNase activity toward the fluorogenic substrate are complex, with a sigmoidal increase in rate up to 10 μM substrate, followed by a marked decrease in rate at 15 and 20 μM substrate. The shape of the rate data suggests that the activity of YoeB Sa1 is influenced by positive cooperativity at low substrate concentrations and by substrate inhibition at high substrate concentrations. However, careful consideration of the assay conditions and the nature of the fluorogenic substrate points to alternative explanations for the apparent cooperativity and substrate inhibition.
In traditional Michaelis−Menten enzyme kinetics, the substrate must be present in significant excess relative to the enzyme so that the substrate concentration is not substantially reduced by formation of the enzyme−substrate complex. 45 In the fluorometric assay, however, YoeB Sa1 (5 μM) is present at a concentration similar to that of the fluorogenic substrate (0.5− 20 μM) in each reaction. Rather than Michaelis−Menten conditions, these enzyme and substrate concentrations resemble those of mutual depletion systems, in which formation of the enzyme−substrate complex significantly reduces the concentrations of both the enzyme and the substrate. 46 Consequently, the classical Michaelis−Menten equation (eq 1) cannot be used to fit the kinetic data of YoeB Sa1 , but this does not necessarily mean that YoeB Sa1 does not follow Michaelis−Menten kinetics. Interestingly, it has been shown that when the concentration of enzyme, [E] T , is equal to or greater than the K m , enzymes that follow Michaelis−Menten kinetics appear to have cooperative activity. The magnitude of the apparent cooperativity increases as [E] T increases relative to K m , causing a concomitant increase in the substrate concentration ([S] T ) 0.5 at which half-maximal velocity is observed. 47 This increase is given by eq 2:
Eq 2 can be used to calculate K m from a plot of reaction velocity versus substrate concentration for enzymes operating under mutual depletion conditions. 46, 47 However, the ability to calculate K m using eq 2 depends on knowledge of V max , which is required to estimate ([S] T ) 0.5 . The reduction in rate observed at 15 and 20 μM substrate precludes extrapolation to V max from the kinetic plot and suggests the influence of substrate inhibition. However, this behavior is likely an artifact of the substrate design, in which a central guanosine RNA residue is flanked on both sides by three or four adenosine RNA residues ( Figure 5A ). These RNA residues could not be removed without abolishing the activity of YoeB Sa1 toward the substrate. Although YoeB Sa1 cleaves primarily after guanosine, minor cleavage is also observed after the neighboring adenosines ( Figure S3 of the Supporting Information). As a result, the activity measured in the fluorometric assay is the sum of the rates at which YoeB Sa1 cleaves after all of the RNA residues in the substrate. The preference for guanosine over adenosine suggests that cleavage after guanosine is faster than cleavage after adenosine. Thus, at nonsaturating substrate concentrations, the observed rate will be influenced primarily by cleavage after guanosine. As the substrate concentration increases, the proportion of cleavage events that are catalyzed after adenosine rather than guanosine will also increase. Eventually, at supersaturating substrate concentrations, the proportion of cleavage events at adenosine will increase to the degree that it will cause a measurable decrease in the overall rate, as observed in Figure 5D .
Consequently, V max for guanosine-specific substrate cleavage cannot be determined from the kinetic data. However, assuming that cleavage after adenosine makes a limited contribution to the measured rate at low substrate concentrations, fitting the kinetic data at substrate concentrations below those at which a measurable decrease in rate occurs will allow extrapolation to an estimate for V max . As it is possible that cleavage after adenosine makes a non-negligible contribution to the overall rate even at low substrate concentrations, this approach will provide minimal estimates only for V max and K m .
The Hill equation (eq 3) was originally derived to describe the cooperative binding of ligands to a protein containing multiple binding sites when one or more ligands are already bound:
where θ is the ratio of occupied binding sites to total binding sites, [L] is the ligand concentration, K A is the association constant, and h is the Hill coefficient, which quantifies the degree of cooperativity. 48 The maximum possible value of h for a perfectly cooperative protein is equal to the number of ligandbinding sites. An h >1 indicates positive cooperativity, where the rate of ligand binding is enhanced by already bound ligands. An h <1 indicates negative cooperativity, where the rate of ligand binding is reduced by already bound ligands. An h equal to 1 indicates no cooperativity, where the rate of ligand binding is unaffected by already bound ligands. If h = 1, the Hill equation (eq 3) reduces to a form similar to that of the Michaelis−Menten equation (eq 1). 44 In addition to ligand-binding proteins, many enzymes exhibit cooperative enhancements or reductions in rate that result from conformational changes induced by enzyme oligomerization or the binding of allosteric effectors. Another smaller but growing class of monomeric enzymes with single ligand-binding sites also exhibits cooperative behavior caused by conformational transformations between two or more enzyme forms with differing substrate affinities. If the rate of conformational interconversion is slower than the rate of the reaction, substrate binding cannot reach equilibrium, resulting in nonhyperbolic, non-Michaelis−Menten kinetics. 49 Therefore, an alternative to mutual depletion as an explanation for the sigmoidal kinetics of YoeB Sa1 is that its activity is cooperative, which would require oligomerization, allosteric effector binding, or a slow conformational change. Comparison of the gel filtration elution volume of YoeB Sa1 with those of known standards indicates that YoeB Sa1 is monomeric under the conditions employed in this assay. Furthermore, the assay buffer contains no known allosteric effectors, indicating 19 which suggests that this area may be conformationally flexible. Moreover, as the primary cellular function of YoeB homologues appears to be ribosomedependent RNase activity, 20,28,50−52 the conformation of YoeB Sa1 that cleaves RNA in a ribosome-dependent fashion may be distinct from the conformations that exist free in solution and cleave free mRNA. Slow conformational change is therefore a plausible explanation for the observed cooperativity in the kinetics of YoeB Sa1 activity toward the fluorogenic substrate.
Regardless of whether the sigmoidal shape of the kinetic data results from mutual depletion or monomeric cooperativity, a modified version of the Hill equation can be used to provide a minimal estimate for V max . The simplest and most common method applied in the analysis of the kinetics of cooperative monomeric enzymes with single ligand-binding sites is a combination of the Hill and Michaelis−Menten equations:
where V max is the maximal reaction velocity, [S] is the substrate concentration, K H is the substrate concentration at which halfmaximal activity is observed, and h is the Hill coefficient. 49 If YoeB Sa1 is cooperative, h quantifies the degree of cooperativity, and K H is equivalent to K m . On the other hand, if mutual depletion occurs, h quantifies the deviation from hyperbolic Michaelis−Menten kinetics, and K m can be calculated using eq 2 with K H = ([S] T ) 0.5 . Eq 4 was therefore used to fit the kinetic data for substrate concentrations between 0.5 and 10 μM to allow extrapolation to a minimal estimate for V max . This gave a V max of 1.05 ± 0.03 pmol/min and a K H of 4.9 ± 0.2 μM, with an h of 2.10 ± 0.09 ( Figure 5D ). Using K H = ([S] T ) 0.5 in eq 2 gives a K m of 2.4 ± 0.2 μM.
■ DISCUSSION
The YoeB Sa1 and YoeB Sa2 toxins from S. aureus were previously found to induce growth arrest and to exhibit cellular RNase activity identical to that of YoeB Ec upon overexpression in E. coli. 28 As YoeB Ec possesses weak ribosome-independent RNase activity with a preference for purine nucleotides in vitro, 19 the possibility that YoeB Sa1 also has ribosome-independent RNase activity was investigated.
One of the most significant obstacles to characterizing the activities and determining the structures of toxic proteins is the difficulty of overexpression in heterologous hosts such as E. coli. Many TA system toxins cannot be obtained in sufficient quantities for characterization because their overexpression arrests growth and/or kills the cells. After the failure of multiple strategies to provide pure, full-length, functional YoeB Sa1 , the discovery that Y88 is required for YoeB Sa1 toxicity in E. coli led to the utilization of UAA mutagenesis to replace this residue with the photocaged amino acid ONBY, which reduced the toxicity of YoeB Sa1 to a sufficient degree to allow overexpression in E. coli.
To the best of our knowledge, this is the first reported use of in vivo UAA mutagenesis to facilitate the isolation and characterization of a toxin from a TA system. Incorporation of ONBY has also been used to overexpress a toxic zinc-finger nuclease in an inactive, nontoxic form in E. coli, 36 suggesting that incorporation of a photocaged version of a critical catalytic residue via UAA mutagenesis may provide a general strategy for allowing expression and characterization of toxic enzymes, provided that an appropriate aaRS/tRNA pair is available. For example, Y87 in YoeB Sa2 is homologous to Y88 in YoeB Sa1 and appears to be important for YoeB Sa2 toxicity in E. coli (unpublished data). Consequently, incorporation of ONBY into YoeB Sa2 using UAA mutagenesis may allow expression of YoeB Sa2 in E. coli for in vitro characterization as well. Furthermore, aaRS/tRNA pairs have also been developed for photocaged cysteine, serine, and lysine. 31 Photocaged versions of aspartate, glutamate, glycine, alanine, and histidine have been synthesized, 53−55 but corresponding aaRS/tRNA pairs do not yet exist. A list of residues identified by mutagenesis and structural data to be responsible for the activity and/or toxicity of a number of TA system toxins is provided in Table 1 .
Notably, each characterized toxin possesses one or more residues corresponding to an accessible photocaged amino acid. Introduction of aaRS/tRNA pairs specific for photocaged aspartate and histidine could allow for the general application of the photocaging strategy for expressing these proteins and studying their activities and cellular roles in vitro and in cells.
YoeB Ec belongs to the RelE structural family. RelE is a ribosome-dependent RNase toxin that is active only in the presence of the ribosome. In the ribosome-bound structure of RelE, Y87 of RelE stacks with the residue upstream of the cleavage site, and its hydroxyl is the closest functional group to the 2′-OH of the cleaved residue, suggesting a dual role in substrate binding and catalysis. Y87 is hypothesized to act as a general base through hydrogen bonding to a water molecule, causing the deprotonation and activation of the 2′-OH for attack of the 3′-phosphodiester bond. 56 The role of Y88 in the catalytic mechanism of YoeB Sa1 is currently unknown and may be different in the presence and absence of the ribosome. Mutation of Y88 in YoeB Sa1 -Y88TAG, YoeB Sa1 -Y88F, and YoeB Sa1 -Y88ONBY sufficiently reduced cellular toxicity to allow overexpression in E. coli (Figure 2 ). The relative yields 
E. coli
Glu24, His28 MqsR of YoeB Sa1 -Y88TAG (5 mg/L) and YoeB Sa1 -Y88F (2.5 mg/L) under identical expression conditions indicate that the Y88TAG mutation renders YoeB Sa1 less toxic than the Y88F mutation, which suggests that both the aromatic ring and hydroxyl functional group of Y88 contribute to cellular RNase activity. Similarly, YoeB Sa1 -Y88F and YoeB Sa1 -Y88ONBY retained the capacity to cleave free mRNA in vitro, albeit at a significantly reduced rate and to a much lesser extent than decaged YoeB Sa1 , while the RNase activity of YoeB Sa1 -Y88TAG was almost completely abolished ( Figure 3C ). These results suggest that both the aromatic ring and hydroxyl functional group of Y88 also contribute to the in vitro activity of YoeB Sa1 , although the exact role played by each of these moieties in ribosomeindependent RNase activity remains unknown.
YoeB Ec was previously found to possess purine-specific ribosome-independent RNase activity with a preference for adenosine over guanosine. 19 In contrast, YoeB Sa1 preferentially cleaves free mRNA after guanosine and to a much lesser extent after adenosine ( Figures 4B and 5B and Figure S3 of the Supporting Information). This specificity was used to design a chimeric fluorogenic substrate to study the kinetics of YoeB Sa1 activity. The resulting kinetic data show a sigmoidal increase in rate at low substrate concentrations followed by a decrease at high substrate concentrations. There are several plausible explanations for these deviations from standard hyperbolic Michaelis−Menten kinetics. First, the sigmoidal shape of the kinetic data may be an artifact of the high enzyme concentration used in these experiments, 47 as it was necessary for the concentrations of YoeB Sa1 and the fluorogenic substrate to be roughly equal (5 and 0.5−20 μM, respectively) to observe YoeB Sa1 activity using the fluorometric assay. Alternatively, a slow transition between inactive and active enzyme conformations may be required for catalysis, resulting in a failure to achieve a steady state of the bound substrate due to the faster speed of enzymatic catalysis. The seeming substrate inhibition is likely an artifact resulting from the unavoidable inclusion of adenosine RNA residues bordering guanosine in the substrate. Cleavage at these adenosine residues is hypothesized to cause a measurable reduction in rate at high substrate concentrations, necessitating the exclusion of these points from the kinetic analysis. It should be noted that these explanations are not mutually exclusive, and two or all three could conceivably be involved in the complex kinetics of YoeB Sa1 activity toward the fluorogenic substrate. The Hill equation was used to fit the sigmoidal portion of the kinetic data to provide minimal estimates for V max and K m . Fitting the kinetic data with the Hill equation (eq 4) for cooperative enzymatic activity gave a V max of 1.05 ± 0.03 pmol/min, a K H of 4.9 ± 0.2 μM, and a Hill coefficient h of 2.10 ± 0.09 ( Figure 5D ). Using eq 2 to convert K H to K m gives a K m of 2.4 ± 0.2 μM.
The relatively low affinity and slow rate observed for YoeB Sa1 cleavage of free mRNA suggest that ribosome-independent RNase activity is unlikely to make a significant contribution to the activity of YoeB Sa1 in cells. This is consistent with prior evidence of only ribosome-dependent RNase activity upon overexpression of YoeB Sa1 in E. coli. 28 YoeB Ec is structurally homologous to RNase Sa from Streptomyces aureofaciens and Barnase from Bacillus amyloliquefaciens, both of which are guanosine-specific RNases, 19 and the catalytic Glu-Arg-His triad found in these and other microbial guanosine-specific RNases is conserved in YoeB Ec , YoeB Sa1 , and YoeB Sa2 . However, YoeB homologues lack a C-terminal extension that orients the nucleotide downstream of the cleavage site via stacking interactions with aromatic side chains. Ribosomal nucleotides may supply these interactions to facilitate proper orientation and cleavage of bound mRNA when YoeB binds in the ribosome, as in the crystal structure of the RelE−ribosome complex. 56 The absence of the C-terminal extension and ribosomal interactions may explain the low affinity and slow rate of the RNase activity of free YoeB Sa1 .
Although YoeB Ec was originally found to have ribosomeindependent RNase activity in in vitro experiments, 19 the only cellular RNase activity observed for YoeB homologues has been ribosome-dependent. 20,28,50−52 This suggests that the ribosome-independent RNase activity of YoeB Sa1 described here may have little relevance in cells apart from the discovery of an artificial activator capable of stabilizing a ribosome-independent RNase conformation of YoeB Sa1 . Then activation of YoeB Sa1 from the YefM−YoeB Sa1 complex in S. aureus could lead to global nonspecific RNA degradation via the guanosine-specific ribosome-independent RNase activity reported here, in addition to translation inhibition via the ribosome-dependent RNase activity described previously, 28 causing growth arrest and possibly eventual death. The fluorometric assay developed for YoeB Sa1 ribosome-independent RNase activity will facilitate high-throughput screens of chemical and peptide libraries to identify molecules capable of activating YoeB Sa1 via prevention of YefM-YoeB Sa1 complex formation or disruption of the complex.
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